Apollo Hospitals Enterprise Limited has informed the Exchange about Scheme of Arrangement
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Apollo Hospitals' board has approved a composite scheme on June 30, 2025 that involves three steps: (1) demerger of its omni-channel pharmacy and digital health business (Apollo 24/7 platform, telehealth) into a new wholly-owned subsidiary called Apollo Healthtech Limited (NewCo), (2) merger of its material subsidiary Apollo HealthCo Limited (AHL) into NewCo, and (3) merger of Keimed Private Limited (a leading wholesale pharma distributor) into NewCo. Under the demerger, AHEL shareholders will receive 195.2 shares of NewCo for every 100 shares of AHEL held. The combined NewCo had FY25 revenue of approximately ₹16,300 crore, with a target of ₹25,000 crore by FY27 and ~7% EBITDA margins. AHEL will retain a 15% stake in NewCo, which is expected to list on NSE and BSE within 18-21 months, subject to NCLT, SEBI, IRDAI, CCI, shareholder, and creditor approvals.
This restructuring allows AHEL shareholders to directly participate in the value of the combined pharmacy distribution and digital health business, eliminating any holding-company discount. The new entity will become Indian Owned and Controlled and aims to consolidate 100% of Apollo Pharmacies by acquiring the remaining 74.5% stake in AMPL, creating a unified, listed omni-channel healthcare platform.